I was thinking for Stroke, inside of Japan only. It would seem to me we would need a Japanese partner to operate inside of Japan. I imagine Pfizer could do that also with all of its connections. So, perhaps you are right.
"Athersys Benefits from Japanese Government Action
We believe the Japanese government has embarked on a novel approach to become a force
within regenerative medicine. With only a handful of regenerative medicine clinical trials having
been run in Japan, and after careful deliberation, the national parliament recently ENACTED a law
that provides for conditional approval of regenerative medicine products (including stem cell
products) IF SAFETY HAS ALREADY BEEN CONFIRMED IN CLINICAL TRIALS, even if efficacy has not been fully demonstrated.
We also believe this law will enable companies like Athersys, Inc. (ATHX) to accelerate
introduction of regenerative medicine therapeutics. In conjunction with the new law, three
patents, granted to ATHX and announced today (January 9), will enable ATHX to introduce
MultiStem® in Japan more rapidly than previously expected, potentially giving the company an
accelerated model for real-life experience with its stem cell therapeutic. One of the patents
covers non-embryonic multipotent stem cells, such as MultiStem and applies to all therapeutic
applications of MultiStem. Another covers the use of multipotent stem cell therapies for treating
immune dysfunctions such as graft-versus-host disease (GvHD) and inflammatory disorders
such as Inflammatory bowel disease (IBD). The third patent covers treatment of brain injuries
such as stroke and traumatic brain injury using multipotent stem cells.
ATHX potential advantage is characterized by a recent report that Pfizer, Inc. (PFE), its
collaborator, has completed patient enrollment of a Phase II clinical study of MultiStem therapy
in patients with ulcerative colitis. ATHX expects initial study results in 2Q-2014"
So, it would seem that we should expect to hear something soon
If the safety profile is superior, as in MultiStems case, they wouldn't necessarily be required either, right? Considering the lack of alternatives, especially in the Stroke trial, where is the harm?
would want to be out of this stock before a possible announcement next week? The next 4 or even 4 1/2 trading days could be more of the same, but Thursday afternoon could see much buying. We shall see.
Could a Japanese partnership be announced? With financial details? It's a possibility, but who knows?
People get nervous before a real, or supposed event and set stop losses too high which triggers selling. Doesn't take much for the domino effect to take place. When investing never bet on fellow investors, just companies. Sometimes you just have to hold tight because you can't rely on the crowd to lead you where you need to go. Learn to anticipate.
2 hours ago the S/P was green. Not much volume today so MM's swing the trades in the direction of less resistance. When they say more buys than sells they mean more transactions were filled at the ask. Its a supply and demand situation, if more people want to sell than buy then the sales goes at the bid. If more people want to buy then it goes at the ask.
only 6% of shareholders are angry. Sometimes you have a bad day, deal with it. Call A.F and see what he can do for you.
with a double blind study I am certain that the nurses are not aware what drug is in the IV bags. I guess if you did a search on something like "fantastic, or miraculous recovery from a stroke" you may find something you may be able to associate with MultiStem.
Buffett likes consumables. Simple products that people use every day. Like Proctor and Gamble products, Coke Cola, General Mills and etc. If you are very young, or if you are investing for a young family member and have the time to invest in products such as that then they are fine. Slow and steady growth with dividends, and do not lose money is his motto. He certainly has proved himself right over the long run.
New companies with low earnings like to spring those kind of details at earnings calls to help soften the effect of not being fully functional yet. I would like to hear news on the Japan front, which is highly possible. They should be seeking a partner inside Japan to help with stroke trials, and sales. Very difficult to go it alone in Japan because of the culture differences and the way of doing business. I am not sure if the process to change the laws to allow faster access to clinical trials has been passed yet, but the next logical set would be to seek an inside partner. Perhaps we will hear of those details.
I was very surprised that the Cleveland Stroke Center video was released for William Cunningham. Perhaps they put a tight lid on information after that video.
Think performance options. That way employee and executive receive stock options based on performance. They can't be accused of insider trading, and investors don't care because they only get them when the stock is doing good. The SEC doesn't typically care either. Makes everyone happy.